Is Lisocabtagene maraleucel on the market?

LisocabtageneLisocabtagene maraleucel) was approved by the U.S. Food and Drug Administration (FDA) on February 5, 2021, and approved by the European Medicines Agency (EMA) in April 2022, and subsequently approved by Health Canada in May of the same year, with the trade name BREYANZI. Brexucabtageneis a chimeric antigen receptor (CAR) T-cell therapy similar to brexucabtagene autoleucel and axicabtagene ciloleucel.

Lisocapitagen was shown to be at least as effective as existing treatment options in patients with diffuse largeB-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B who had received at least two prior therapies. Lisocabbutanol has also shown benefit in patients with relapsed or refractory large B-cell lymphoma, whose cancer relapsed soon after or failed to respond to previous treatments. Serious side effects may occur, especially cytokine release syndrome.

CAR T-cell therapy has changed the way B-cell lymphoma is treated, significantly improving survival rates compared with standard therapies. However, data on the efficacy of CAR T-cell therapy in less severe B-cell lymphomas are still lacking. Despite adverse effects, most patients treated with lisocabetagen experienced an overall improvement in their quality of life within 1 year.

Since Lisocaptagen has been on the market for a short time, there may be less information on its price and other related information.